Does Rallies show 13F holders for CRNX?

Yes. Rallies tracks hedge fund and 13F ownership data for CRNX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CRNX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRNX. It does not provide personalized investment advice.

CRNX (Crinetics Pharmaceuticals, Inc.) Stock Analysis - Hedge Fund Holdings

Crinetics Pharmaceuticals, Inc. (CRNX) is a publicly traded Healthcare sector company. As of May 21, 2026, CRNX trades at $36.28 with a market cap of $3.66B and a P/E ratio of -7.30. CRNX moved +3.84% today. Year to date, CRNX is -24.72%; over the trailing twelve months it is +15.62%. Its 52-week range spans $24.10 to $62.53. Analyst consensus is strong buy with an average price target of $86.00. Rallies surfaces CRNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CRNX stock?

Hedge funds tracked by Rallies that own CRNX include Farallon Capital, Orbimed Advisors, and Duquesne Family. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Crinetics Pharmaceuticals, Inc..

CRNX Key Metrics

Key financial metrics for CRNX
Metric	Value
Price	$36.28
Market Cap	$3.66B
P/E Ratio	-7.30
EPS	$-4.95
Dividend Yield	0.00%
52-Week High	$62.53
52-Week Low	$24.10
Volume	581.00K
Avg Volume	0
Revenue (TTM)	$7.70M
Net Income	$-465.32M
Gross Margin	86.02%

Top Hedge Funds Holding CRNX

Farallon Capital holds 8.34M shares of CRNX, changed +20.27% as of Mar 31, 2026.
Orbimed Advisors holds 999.00K shares of CRNX, changed +0.00% as of Mar 31, 2026.
Duquesne Family holds 122.70K shares of CRNX, changed -60.29% as of Dec 31, 2024.

Latest CRNX News

Crinetics Launches Palsonfi with 50% QuickStart Patients, Maintains $1B Cash Runway — Feb 27, 2026
Crinetics Posts $6.2M Q4 Revenue with 125 Prescribers and $1.4B Cash — Feb 27, 2026
Crinetics Books Over $5M Q4 PALSONIFY Revenue, Phase 2 Atumelnant Shows 67% A4 Reduction — Jan 7, 2026
Crinetics Prices 7.62M Share Offering at $45.95 to Raise $350M — Jan 7, 2026
Crinetics Launches 7.62M-Share Offering to Raise $350M and Reports $5M Q4 PALSONIFY Revenue — Jan 7, 2026

Recent CRNX Insider Trades

Knight Jeff E. sold 85.16K (~$3.42M) on Apr 8, 2026.
Knight Jeff E. sold 5.95K (~$220.80K) on Mar 16, 2026.
Knight Jeff E. sold 3.96K (~$149.61K) on Mar 16, 2026.

CRNX Analyst Consensus

10 analysts cover CRNX: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $86.00.

Common questions about CRNX

Who owns CRNX stock?: Hedge funds tracked by Rallies that own CRNX include Farallon Capital, Orbimed Advisors, and Duquesne Family. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Crinetics Pharmaceuticals, Inc..
Does Rallies show 13F holders for CRNX?: Yes. Rallies tracks hedge fund and 13F ownership data for CRNX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CRNX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRNX. It does not provide personalized investment advice.